Introduction {#section5-1756284819858511}
============

*Helicobacter pylori* infection is associated with peptic ulcers, gastric-mucosa-associated lymphoid tissue lymphomas, and gastric cancer.^[@bibr1-1756284819858511],[@bibr2-1756284819858511]^ Earlier, we have shown the trends with first- and second-line eradication therapies for *H. pylori* in Japan.^[@bibr3-1756284819858511],[@bibr4-1756284819858511]^ However, the environment surrounding *H. pylori* eradication treatment is dramatically changing. In 2000, first-line eradication, a triple therapy based on a proton-pump inhibitor (PPI), amoxicillin (AMPC), and clarithromycin (CAM), was approved and covered by the national health insurance scheme for peptic ulcers in Japan.^[@bibr5-1756284819858511]^ Moreover, second-line eradication, a triple therapy based on a PPI, AMPC, and metronidazole (MTZ), was also approved and covered by insurance in 2007.^[@bibr5-1756284819858511]^ To prevent gastric carcinogenesis, the Japanese Ministry of Health, Labor and Welfare approved the insurance coverage of *H. pylori* eradication therapy in all patients with *H. pylori*-associated chronic gastritis in 2013.^[@bibr6-1756284819858511][@bibr7-1756284819858511]--[@bibr8-1756284819858511]^ Moreover, vonoprazan (VPZ), a first-in-class potassium-competitive acid blocker (P-CAB), which exhibited more rapid, strong, and continuous gastric acid suppression compared with conventional PPIs, was introduced in the market in 2015.^[@bibr9-1756284819858511],[@bibr10-1756284819858511]^ Meanwhile, the aging of Japan's demographic structure is becoming pronounced. In 2015, 12.8% of population were over 75 years of age in Japan.^[@bibr11-1756284819858511]^ The influence of aging on *H. pylori* eradication is less well understood.

Therefore, we examined the trend of eradication rate of *H. pylori* in the metropolitan area and examined factors that were associated with successful eradication.

Subjects and methods {#section6-1756284819858511}
====================

Study population {#section7-1756284819858511}
----------------

A retrospective analysis of results of first- and second-line eradication therapies was conducted by the Tokyo Hp Study Group, which comprised staff members of 20 facilities in the Tokyo metropolitan area in Japan.

To investigate changes in the first- and second-line eradication rates, we retrospectively examined data of patients who received first-line eradication therapy with a PPI/P-CAB \[rabeprazole (RPZ) 10 mg twice a day, lansoprazole (LPZ) 30 mg twice a day, omeprazole (OPZ) 20 mg twice a day, esomeprazole (EPZ) 20 mg twice a day, or VPZ 20 mg twice a day\], AMPC (750 mg twice a day), and CAM (200 or 400 mg twice a day) for 1 week in a 4--6 month period each year from 2013 to 2018, and second-line eradication therapy with a PPI/P-CAB (RPZ 10 mg twice a day, LPZ 30 mg twice a day, OPZ 20 mg twice a day, EPZ 20 mg twice a day, or VPZ 20 mg twice a day), AMPC (750 mg twice a day), and MTZ (250 mg twice a day) for 1 week in a whole year from 2013 to 2018. The data were extracted from the medical records, of those patients who were prescribed the combination of drugs. Patients who were not treated for *H. pylori* eradication or who did not receive an upper gastrointestinal endoscopy before eradication were excluded. The patients were interviewed for treatment naïve or treatment experienced before the eradication treatment. The patients had undergone upper gastrointestinal endoscopy prior to *H. pylori* eradication therapy, and the findings of chronic atrophic gastritis were confirmed according to the Kyoto classifications, and background diseases were investigated.^[@bibr12-1756284819858511],[@bibr13-1756284819858511]^ *H. pylori* infection was confirmed through at least one of the following methods before first-line treatment: the *H. pylori* stool antigen test (HpSA), urea breath test (UBT), rapid urease test, serology, culture, and histology. After a diagnosis of first-line treatment failure with UBT or HpSA, the patients were treated with second-line treatment. This study protocol was approved by the Committee for Medical Ethics of Keio University School of Medicine (no. 20160051; 22 June 2016) and was conducted in accordance with the tenets of the Declaration of Helsinki 1975, and its later amendment in 1983. Written informed consent was not obtained, and informed consent included an opt-out clause according to the Medical Ethics Committee. The study was observational and reported in accordance with the Strengthening Reporting of Observational Studies in Epidemiology guidelines.^[@bibr14-1756284819858511]^

Study design {#section8-1756284819858511}
------------

To investigate changes in the first- and second-line eradication rates, the annual eradication rate was compared with that in the base period, the eradication rate of 2013. Associated factors (age, sex, choice of PPIs or VPZ, the dosage of CAM and background diseases of the stomach) for successful eradication were analyzed. The elderly population is defined as people aged 75 years and over.^[@bibr15-1756284819858511]^ At least 4 weeks after the end of eradication therapy, successful eradication was confirmed using UBT or HpSA.^[@bibr16-1756284819858511][@bibr17-1756284819858511]--[@bibr18-1756284819858511]^ The cut-off value for a negative UBT was \<2.5%.^[@bibr16-1756284819858511]^ Values of UBT between 2.5 and 5.0% were considered as being in the gray zone.^[@bibr19-1756284819858511]^

Associated factors of UBT gray zone in the patients with first- and second-line eradication failure (age, sex, choice of PPIs or VPZ, first- or second-line treatment, and dosage of CAM) were analyzed.

Statistical analysis {#section9-1756284819858511}
--------------------

All patients were evaluated with the intention to treat (ITT), in which patients without a final *H. pylori* determination, or with protocol violations, were considered treatment failures. The per-protocol (PP) analysis included all patients who took at least 80% of the prescribed medication and completed the final *H. pylori* status assessment.^[@bibr20-1756284819858511]^ Comparisons of the annual eradication rate and that of the base period were conducted using Fisher's exact test in the ITT and PP analysis. Univariate logistic regression analysis was used to evaluate factors associated with successful eradication and UBT gray zone. Subsequently, multivariate logistic regression analysis was performed by adjusting for factors that showed a marginally significant association (*p* \< 0.1) in the univariate analysis. Statistical analyses were performed using SPSS 25 for Windows (SPSS Inc., Chicago, IL, USA). Data are expressed as means ± standard deviation.

Results {#section10-1756284819858511}
=======

Patient characteristics {#section11-1756284819858511}
-----------------------

A total of 4097 and 3572 were enrolled in this study ([Tables 1](#table1-1756284819858511){ref-type="table"} and [2](#table2-1756284819858511){ref-type="table"}). The proportions of PPI gradually decreased from 2013 to 2018 in both the first- and second-line regimens \[[Tables 1](#table1-1756284819858511){ref-type="table"} and [2](#table2-1756284819858511){ref-type="table"}, [Figure 1(c)](#fig1-1756284819858511){ref-type="fig"} and [2(c)](#fig2-1756284819858511){ref-type="fig"}\]. The percentage of LPZ in the first-line regimen was rapidly decreasing from 2013 to 2018; it was 81.8% in 2013 and only 3.4% in 2018. The percentage of RPZ was also decreasing from 2014 to 2018, being 35.4% in 2013 and only 0.8% in 2018. As a second-line regimen, the percentage of LPZ in the first-line regimen was rapidly decreasing from 2013 to 2018, being 65.7% in 2013 and only 1.6% in 2018. The percentage of RPZ was also decreasing from 2014 to 2018, as it was 41.3% in 2013 and only 6.8% in 2018. In contrast, VPZ was introduced in 2015, and its proportions dramatically increased toward 2018 in both the first- and second-line regimens \[[Tables 1](#table1-1756284819858511){ref-type="table"} and [2](#table2-1756284819858511){ref-type="table"}, [Figure 1(c)](#fig1-1756284819858511){ref-type="fig"} and [2(c)](#fig2-1756284819858511){ref-type="fig"}\]. In 2018, the proportions of VPZ were 95.5% and 90.2% in the first- and second-line regimens, respectively. Regarding background diseases of the stomach, the proportions of peptic ulcer disease gradually decreased, and those of chronic gastritis gradually increased from 2013 to 2018 in both first- and second-line regimens ([Tables 1](#table1-1756284819858511){ref-type="table"} and [2](#table2-1756284819858511){ref-type="table"}).

###### 

Patients' demographics of first-line therapy.

![](10.1177_1756284819858511-table1)

                              2013          2014          2015          2016          2017          2018
  --------------------------- ------------- ------------- ------------- ------------- ------------- -------------
  Total                       813           773           766           684           438           623
  Male/female                 412/401       409/364       412/354       359/325       228/210       336/287
  Age, mean ± SD              60.6 ± 12.9   59.3 ± 13.3   58.6 ± 13.8   59.7 ± 13.7   58.1 ± 15.2   59.4 ± 13.9
  Rabeprazole (%)             70 (8.6)      274 (35.4)    252 (32.9)    92 (13.5)     46 (10.5)     5 (0.8)
  Lansoprazole (%)            665 (81.8)    459 (59.4)    155 (20.2)    72 (10.5)     13 (3.0)      21 (3.4)
  Omeprazole (%)              0 (0)         1 (0.1)       0 (0)         0 (0)         1 (0.2)       1 (0.2)
  Esomeprazole (%)            78 (9.6)      39 (5.0)      10 (1.3)      7 (1.0)       1 (0.2)       1 (0.2)
  Vonoprazan (%)              0 (0)         0 (0)         349 (45.6)    513 (75.0)    377 (86.1)    595 (95.5)
  CAM 400 mg/800 mg per day   450/363       551/222       528/238       509/175       343/95        481/142
  Peptic ulcer disease (%)    196 (24.1)    166 (21.5)    150 (19.6)    104 (15.2)    72 (16.4)     83 (13.3)
  Chronic gastritis (%)       561 (69.0)    543 (70.2)    594 (77.5)    556 (81.3)    336 (76.7)    495 (79.5)
  MALT lymphoma (%)           1 (0.1)       0 (0)         0 (0)         6 (0.9)       1 (0.2)       4 (0.6)
  Gastric polyp (%)           18 (2.2)      23 (3.0)      10 (1.3)      6 (0.9)       7 (1.6)       10 (1.6)
  Early gastric cancer (%)    24 (3.0)      13 (1.7)      8 (1.0)       10 (1.5)      20 (4.6)      23 (3.7)
  Other disease (%)           14 (1.7)      28 (3.6)      4 (0.5)       2 (0.3)       2 (0.5)       8 (1.3)

SD, standard deviation; CAM, clarithromycin; MALT, mucosa-associated lymphoid tissue.

###### 

Patients' demographics of second-line therapy.

![](10.1177_1756284819858511-table2)

                             2013          2014          2015          2016          2017          2018
  -------------------------- ------------- ------------- ------------- ------------- ------------- -------------
  Total                      744           804           742           598           315           369
  Male/female                361/383       409/395       381/361       321/277       145/170       197/172
  Age, mean ± SD             59.6 ± 13.7   59.4 ± 13.5   57.9 ± 13.4   59.4 ± 14.2   58.8 ± 13.5   59.1 ± 13.8
  Rabeprazole (%)            196 (26.3)    332 (41.3)    260 (35.0)    113 (18.9)    40 (12.7)     25 (6.8)
  Lansoprazole (%)           490 (65.9)    416 (51.7)    174 (23.5)    70 (11.7)     22 (7.0)      6 (1.6)
  Omeprazole (%)             11 (1.5)      2 (0.2)       0 (0)         1 (0.2)       3 (1.0)       0 (0)
  Esomeprazole (%)           47 (6.3)      54 (6.7)      5 (0.7)       6 (1.0)       2 (0.6)       5 (1.0)
  Vonoprazan (%)             0 (0)         0 (0)         303 (40.8)    408 (68.2)    248 (78.7)    333 (90.2)
  Peptic ulcer disease (%)   167 (22.4)    151 (18.8)    113 (15.2)    86 (14.4)     37 (11.7)     44 (11.9)
  Chronic gastritis (%)      498 (66.9)    562 (69.9)    597 (80.5)    472 (78.9)    258 (81.9)    300 (81.3)
  MALT lymphoma (%)          2 (0.3)       1 (0.1)       1 (0.1)       1 (0.2)       2 (0.6)       0 (0)
  Gastric polyp (%)          33 (4.4)      15 (1.9)      10 (1.3)      12 (2.0)      8 (2.5)       8 (2.2)
  Early gastric cancer (%)   31 (4.2)      33 (4.1)      17 (2.3)      22 (3.7)      9 (2.9)       13 (3.5)
  Other disease (%)          13 (1.7)      42 (5.2)      4 (0.5)       5 (0.8)       1 (0.3)       4 (1.1)

SD, standard deviation; MALT, mucosa-associated lymphoid tissue.

![Annual changes of the eradication rate of first-line therapy and the proportion of PPIs/P-CAB in the first-line regimen.\
(a) Annual changes of the eradication rate of first-line therapy in ITT and PP; (b) annual changes of the eradication rate of first-line therapy divided into each PPIs/P-CAB; (c) the proportion of PPIs/P-CAB in the first-line regimen. (a) Once the eradication rate decreased from 2013 to 2014 (*p* = 0.02 and \<0.01, ITT and PP, respectively), after that, the rate showed backward rising from 2015 to 2018 in the first-line eradication (*p* \< 0.01, \<0.01, \<0.01, \<0.01 and *p* \< 0.01, \<0.01, \<0.01, \<0.01, ITT and PP, respectively); (b) the eradication rates of VPZ were constantly over 87% from 2015 to 2018 (87.2%, 87.5%, 90.8 and 90.6% in PP, respectively). As PPI-containing regimens, the eradication rates of LPZ range from 60.0% to 80.0%, and that of RPZ range from 67.1% to 87.5%. Five and less in each item are not described in the graph; (c) VPZ was introduced in 2015, and its proportions dramatically increased toward 2018 in the first-line regimens. In 2018, the proportion of VPZ was 95.5%.\
ITT, intention to treat; PP, per protocol; VPZ, vonoprazan; PPI, proton-pump inhibitor; LPZ, lansoprazole; RPZ, rabeprazole.](10.1177_1756284819858511-fig1){#fig1-1756284819858511}

![Annual changes of the eradication rate of second-line therapy and the proportion of PPIs/P-CAB in the second-line regimen.\
(a) Annual changes of the eradication rate of second-line therapy in ITT and PP; (b) annual changes of the eradication rate of second-line therapy divided into each PPIs/P-CAB; (c) the proportion of PPIs/P-CAB in the second-line regimen. (a) Once the eradication rate decreased from 2013 to 2014 (*p* \< 0.01 and \<0.01, ITT and PP, respectively), the rate generally continued to stabilize (*p* = 0.65, 0.07, 0.50, 0.17 and *p* = 0.48, 0.19, 0.46, 1.00, ITT and PP, respectively); (b) the eradication rates of VPZ were constantly over 88% from 2015 to 2018 (88.4%, 89.2%, 92.8 and 90.6% in PP, respectively). As PPI-containing regimens, the eradication rates of LPZ range from 76.7% to 95.0%, and that of RPZ range from 82.6% to 89.2%. Five and less in each item are not described in the graph; (c) VPZ was introduced in 2015, and its proportions dramatically increased toward 2018 in the second-line regimens. In 2018, the proportion of VPZ was 90.2%.\
ITT, intention to treat; PP, per protocol; VPZ, vonoprazan; PPI, proton-pump inhibitor; LPZ, lansoprazole; RPZ, rabeprazole.](10.1177_1756284819858511-fig2){#fig2-1756284819858511}

Annual changes of the eradication rate {#section12-1756284819858511}
--------------------------------------

The overall first-line eradication rates of PPI, AMPC and CAM triple therapy were 69.4% and 62.7% in PP and ITT, respectively, and those of VPZ, AMPC and CAM triple therapy were 89.1% and 81.4% in PP and ITT, respectively. The eradication rates of the first-line eradication from 2013 to 2018 were 64.6%, 58.7%, 72.5%, 77.3%, 79.9% and 79.8% in ITT and 71.8%, 63.7%, 78.5%, 84.6%, 89.7 and 90.1% in PP \[[Figure 1(a)](#fig1-1756284819858511){ref-type="fig"}\]. After the eradication rate decreased from 2013 to 2014 (*p* = 0.02 and *p* \< 0.01 for ITT and PP, respectively), the rate showed backward increase from 2015 to 2018 in the first-line eradication \[*p* \< 0.01, 0.01, 0.01, 0.01 and *p* \< 0.01, 0.01, 0.01, 0.01 for ITT and PP, respectively; [Figure 1(a)](#fig1-1756284819858511){ref-type="fig"}\]. The eradication rates of VPZ were constantly over 87% from 2015 to 2018 \[87.2%, 87.5%, 90.8 and 90.6% in PP, respectively; [Figure 1(b)](#fig1-1756284819858511){ref-type="fig"}\]. As PPI-containing regimens, the eradication rates of LPZ range from 60.0% to 80.0%, and that of RPZ range from 67.1% to 87.5% \[[Figure 1(b)](#fig1-1756284819858511){ref-type="fig"}\].

The overall second-line eradication rates of PPIs, AMPC, and MTZ regimen were 86.6% and 77.6% in PP and ITT, respectively, and those of the VPZ, AMPC, and MTZ regimens were 90.1% and 80.0% in PP and ITT, respectively. The rate of the second-line eradication was 80.2%, 73.6%, 81.3%, 76.1%, 78.4% and 83.7% in ITT and 90.0%, 82.6%, 88.8%, 87.5%, 91.8% and 90.1% in PP \[[Figure 2(a)](#fig2-1756284819858511){ref-type="fig"}\]. After the eradication rate decreased from 2013 to 2014 (*p* \< 0.01 and *p* \< 0.01 for ITT and PP, respectively), the rate generally continued to stabilize \[*p* = 0.65, 0.07, 0.50, 0.17 and *p* = 0.48, 0.19, 0.46, 1.00 for ITT and PP, respectively; [Figure 2(a)](#fig2-1756284819858511){ref-type="fig"}\]. The eradication rates of VPZ were constantly over 88% from 2015 to 2018 \[88.4%, 89.2%, 92.8 and 90.6% in PP, respectively; [Figure 2(b)](#fig2-1756284819858511){ref-type="fig"}\]. As PPI-containing regimens, the eradication rates of LPZ range from 76.7% to 95.0% and that of RPZ range from 82.6% to 89.2% \[[Figure 2(b)](#fig2-1756284819858511){ref-type="fig"}\].

Associated factors for the eradication success in each regimen {#section13-1756284819858511}
--------------------------------------------------------------

Using univariate logistic regression analysis, sex \[female, *p* = 0.03; odds ratio (OR) 0.84; 95% confidence interval (CI) 0.72--0.98\], age of 75 years or older (*p* = 0.04; OR 0.79; 95% CI 0.64--0.99) and choices of PPIs /P-CAB (PPIs, *p* \< 0.01; OR 0.28; 95% CI 0.23--0.33) were associated with the eradication rate in first-line therapy ([Table 3](#table3-1756284819858511){ref-type="table"}). Age of 50 years or older (*p* = 0.67; OR 0.96; 95% CI 0.80--1.16), and the dose of CAM (CAM 800 mg, *p* = 0.41; OR 1.07; 95% CI 0.91--1.27) were not associated with successful eradication ([Table 3](#table3-1756284819858511){ref-type="table"}). Age of 75 years or older (*p* = 0.01; OR 0.77; 95% CI 0.60--0.94) and choice of PPIs/P-CAB (PPIs, *p* \< 0.01; OR 0.28; 95% CI 0.23--0.33) were independently associated with eradication failure in the multivariate logistic regression analysis ([Table 3](#table3-1756284819858511){ref-type="table"}). In the second-line therapy, using univariate logistic regression analysis, age of 75 years or older (*p* \< 0.01; OR 0.55; 95% CI 0.42--0.72) and choice of PPIs/P-CAB (PPIs, *p* \< 0.01; OR 0.71; 95% CI 0.57--0.90) were associated with the eradication rate ([Table 3](#table3-1756284819858511){ref-type="table"}). Sex and age of 50 years or older was not associated with successful eradication (female, *p* = 0.29; OR 1.12; 95% CI 0.91--1.39 and age of 50 years or older, *p* = 0.45; OR 0.91; 95% CI 0.71--1.17; [Table 3](#table3-1756284819858511){ref-type="table"}). Age of 75 years or older (*p* \< 0.01; OR 0.55; 95% CI 0.42--0.71) and choice of PPIs/P-CAB (PPIs, *p* \< 0.01; OR, 0.71; 95% CI, 0.56--0.89) were independently associated with eradication failure in the multivariate logistic regression analysis ([Table 3](#table3-1756284819858511){ref-type="table"}).

###### 

Factors associated with eradication success in each regimen.

![](10.1177_1756284819858511-table3)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            Eradicated   Not eradicated   Univariate analysis\                                                          Multivariate analysis OR (95% CI)^\$^
                                                          OR (95% CI)                                                                   
  ------------------------- ------------ ---------------- ----------------------------------------------------------------------------- -----------------------------------------------------------------------------
  First-line eradication    *n* = 2911   *n* = 808                                                                                      

   Dosage of CAM                                                                                                                        

    CAM 800 mg/day          843          246              1.07 (0.91--1.27)                                                             

    CAM 400 mg/day          2068         562                                                                                            

   Sex                                                                                                                                  

    Female                  1546         393              0.84 (0.72--0.98)^[\*](#table-fn3-1756284819858511){ref-type="table-fn"}^     0.88 (0.75--1.03)

    Male                    1365         415                                                                                            

   Age                                                                                                                                  

    ⩾50 years               2208         618              0.96 (0.80--1.16)                                                             

    ⩾75 years               385          130              0.79 (0.64--0.99)^[\*](#table-fn3-1756284819858511){ref-type="table-fn"}^     0.75 (0.60--0.94)^[\*](#table-fn3-1756284819858511){ref-type="table-fn"}^

   Choice of PPI/P-CAB                                                                                                                  

    PPIs                    1418         625              0.28 (0.23--0.33)^[\*\*](#table-fn4-1756284819858511){ref-type="table-fn"}^   0.28 (0.23--0.33)^[\*\*](#table-fn4-1756284819858511){ref-type="table-fn"}^

    P-CAB                   1493         183                                                                                            

  Second-line eradication   *n* = 2809   *n* = 389                                                                                      

   Sex                                                                                                                                  

    Female                  1417         185              1.12 (0.91--1.39)                                                             

    Male                    1392         204                                                                                            

   Age                                                                                                                                  

    ⩾50 years               2116         300              0.91 (0.71--1.17)                                                             

    ⩾75 years               370          84               0.55 (0.42--0.72)^[\*\*](#table-fn4-1756284819858511){ref-type="table-fn"}^   0.55 (0.42--0.71)^[\*\*](#table-fn4-1756284819858511){ref-type="table-fn"}^

   Choice of PPI/P-CAB                                                                                                                  

    PPIs                    1776         275              0.71 (0.57--0.90)^[\*\*](#table-fn4-1756284819858511){ref-type="table-fn"}^   0.71 (0.56--0.89)^[\*\*](#table-fn4-1756284819858511){ref-type="table-fn"}^

    P-CAB                   1033         114                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*p* \< 0.05.

*p* \< 0.01.

Multivariate logistic regression analysis was performed, adjusted by marginally associated factors (*p* \< 0.1) in univariate analysis. Sex, age, and choice of PPIs/P-CAB in first-line eradication, and age and choice of PPIs/P-CAB in second-line eradication were included in the analyses.

CAM, clarithromycin; PPI, proton-pump inhibitor; P-CAB, potassium-competitive acid blocker; OR, odds ratio; CI, confidence interval.

Proportions of UBT gray zone in patients with eradication failure {#section14-1756284819858511}
-----------------------------------------------------------------

A total of 1171 (761 and 410 in first- and second-line therapy, respectively) patients were diagnosed as eradication failure with UBT. The overall proportions of UBT gray zone in patients with eradication failure were 21.3% (250/1171). A total of 15.2% (118/761) and 32.2% (132/410) in the first- and second-line therapy were UBT gray zone, respectively. Comparing the elderly (aged 75 years or older) and younger populations (aged less than 75 years) in patients, 19.9% (192/964) and 28.0% (58/207) in the younger population and the elderly were UBT gray zone, respectively. Comparing male and female, 25.2% (146/580) and 17.6% (104/591) in male and female were UBT gray zone, respectively. Comparing P-CAB- and PPI-containing regimens, 27.8% (85/306) and 19.1% (165/865) in P-CAB and PPI were UBT gray zone, respectively. Associated factors for UBT gray zone in eradication failure population were analyzed with univariate and multivariate logistic regression analysis ([Table 4](#table4-1756284819858511){ref-type="table"}). Using univariate logistic regression analysis, second-line therapy (*p* \< 0.01; OR 2.59; 95% CI 1.95--3.44), male (*p* \< 0.01; OR 1.58; 95% CI 1.19--2.09), age of 75 years or older (*p* = 0.01; OR 1.57; 95% CI 1.11--2.20), and choice of P-CAB (*p* \< 0.01; OR 1.63; 95% CI 1.21--2.21) were associated with UBT gray zone, respectively ([Table 4](#table4-1756284819858511){ref-type="table"}). Second-line therapy (*p* \< 0.01; OR 2.49; 95% CI 1.86--3.31), male sex (*p* \< 0.01; OR 1.54; 95% CI 1.13--2.10), age of 75 years or older (*p* = 0.02; OR 1.54; 95% CI 1.08--2.18), and choice of P-CAB (*p* \< 0.01; OR 1.54; 95% CI 1.13--2.10) were independently associated with eradication failure in the multivariate logistic regression analysis ([Table 4](#table4-1756284819858511){ref-type="table"}).

###### 

Associated factors for UBT gray zone in eradication failure population.

![](10.1177_1756284819858511-table4)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                      UBT gray zone\   UBT high\         Univariate analysis\                                                          Multivariate analysis OR (95% CI)^\$^
                                      2.5 to 4.9 (%)   5.0 \< or = (%)   OR (95% CI)                                                                   
  ----------------------------------- ---------------- ----------------- ----------------------------------------------------------------------------- -----------------------------------------------------------------------------
  First- or second-line eradication   *n* = 250        *n* = 921                                                                                       

   Second-line eradication            132              278               2.59 (1.95--3.44)^[\*\*](#table-fn8-1756284819858511){ref-type="table-fn"}^   2.49 (1.86--3.31)^[\*\*](#table-fn8-1756284819858511){ref-type="table-fn"}^

   First-line eradication             118              643                                                                                             

  Dosage of CAM                                                                                                                                        

    CAM 800 mg/day                    74               447               1.36 (0.90--2.04)                                                             

    CAM 400 mg/day                    44               196                                                                                             

  Sex                                                                                                                                                  

    Male                              146              434               1.58 (1.19--2.09)^[\*\*](#table-fn8-1756284819858511){ref-type="table-fn"}^   1.54 (1.13--2.10)^[\*\*](#table-fn8-1756284819858511){ref-type="table-fn"}^

    Female                            104              487                                                                                             

  Age                                                                                                                                                  

    ⩾75 years                         58               149               1.57 (1.11--2.20)^[\*](#table-fn7-1756284819858511){ref-type="table-fn"}^     1.54 (1.08--2.18)^[\*](#table-fn7-1756284819858511){ref-type="table-fn"}^

  Choice of PPI/P-CAB                                                                                                                                  

    P-CAB (vonoprazan)                85               221               1.63 (1.21--2.21)^[\*\*](#table-fn8-1756284819858511){ref-type="table-fn"}^   1.54 (1.13--2.10)^[\*\*](#table-fn8-1756284819858511){ref-type="table-fn"}^

    PPIs                              165              700                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*p* \< 0.05.

*p* \< 0.01.

Multivariate logistic regression analysis was performed adjusted by marginally associated factors (P\<0.1) in univariate analysis. First- or second-line eradication, sex, age and choices of PPIs/P-CAB were included in the analyses.

UBT, urea breath test; CAM, clarithromycin; PPI, proton-pump inhibitor; P-CAB, potassium-competitive acid blocker.

Discussion {#section15-1756284819858511}
==========

In this study, we showed changes in first- and second-line eradication rate from 2013 to 2018. We previously reported AMPC, CAM, and PPI triple therapy achieving 79.4% of successful eradication of PP in 2001.^[@bibr4-1756284819858511]^ Thereafter, the eradication rate gradually decreased; the rate decreased to 63.7% in 2014 \[[Figure 1(a)](#fig1-1756284819858511){ref-type="fig"}\]. An increase in CAM-resistant *H. pylori* has been a serious problem in Japan. There was an increase, from 6.2% in 1995 to 22.1% in 2000--2001, in the proportion of patients infected with CAM-resistant *H. pylori.*^[@bibr21-1756284819858511]^ Furthermore, the resistance rate increased yearly; from 18.9% in 2002--2003 to 21.1% in 2003--2004, and 27.7% in 2004--2005.^[@bibr22-1756284819858511]^ Murakami and colleagues reported that the eradication rate of CAM-resistant strains treated with LPZ, AMPC, and CAM triple therapy was 40.0%, and that of CAM-susceptible strains was 97.3%.^[@bibr9-1756284819858511]^ Therefore, the proportion of CAM-resistant strains is one of the most important factors influencing successful eradication with PPIs, AMPC, and CAM triple therapy.

The multivariate logistic regression analysis highlighted that use of PPIs was an independent factor affecting eradication failure in first-line eradication therapy in this study (*p* \< 0.01; [Table 3](#table3-1756284819858511){ref-type="table"}). In our study, the overall eradication rate of PPI, AMPC, and CAM triple therapy was 69.4% in PP, and that of VPZ, AMPC, and CAM triple therapy was 89.1% in PP. Ample studies have demonstrated that efficacy of VPZ, AMPC, and CAM triple therapy was superior to that of PPIs, AMPC, and CAM triple therapy.^[@bibr9-1756284819858511],[@bibr10-1756284819858511],[@bibr23-1756284819858511][@bibr24-1756284819858511][@bibr25-1756284819858511]--[@bibr26-1756284819858511]^ In our study, the proportion of VPZ-containing therapy in first-line therapy started at 45.6% in 2015, sharply increasing to 95.5% in 2018. A rapid increase in the proportion of VPZ-containing therapy should reflect the backward increase of the successful eradication ratio from 2015 to 2018.

Regarding second-line eradication, after the eradication rate decreased from 2013 to 2014, the rate generally continued to stabilize until 2018. The overall eradication rate of the PPI, AMPC, and MTZ regimen was 86.6%, and that of the VPZ, AMPC, and MTZ regimen was 90.1%, in this study. The multivariate logistic regression analysis revealed that choice of VPZ was an independent factor affecting successful eradication in second-line therapy ([Table 3](#table3-1756284819858511){ref-type="table"}). The proportions of VPZ dramatically increased toward 2018 in the second-line regimen \[[Table 2](#table2-1756284819858511){ref-type="table"} and [Figure 2(c)](#fig2-1756284819858511){ref-type="fig"}\]; however, secular changes in the eradication rate of each year remained only in a small range \[[Figure 2(a)](#fig2-1756284819858511){ref-type="fig"}\]. MTZ resistance in Japan was reported as lower, and no change has been observed in the trend.^[@bibr21-1756284819858511],[@bibr22-1756284819858511],[@bibr27-1756284819858511]^ The eradication rates of the PPI, AMPC, and MTZ regimen were reported to be high at 84--97% in Japan;^[@bibr3-1756284819858511],[@bibr10-1756284819858511],[@bibr27-1756284819858511][@bibr28-1756284819858511][@bibr29-1756284819858511]--[@bibr30-1756284819858511]^ hence, there are no previous reports regarding the superiority of the VPZ, AMPC, and MTZ regimen for second-line eradication.^[@bibr10-1756284819858511],[@bibr31-1756284819858511]^ The present study, to our knowledge, is the first report showing that efficacy of the VPZ, AMPC and MTZ second-line regimen showed a significant difference compared with the PPI, AMPC, and MTZ regimen. Murakami and colleagues reported that the second-line eradication rate for RPZ, AMPC and MTZ in MTZ-sensitive strains was higher than that in MTZ-resistant strains (97% *versus* 82%).^[@bibr32-1756284819858511]^ Our results suggest that the VPZ, AMPC, and MTZ regimen might be more effective than the PPI, AMPC, and MTZ regimen for MTZ-resistant strains. To confirm this hypothesis, a large-scale prospective study with evaluation of the relationship between MTZ resistance and the VPZ, AMPC, and MTZ regimen is warranted.

Our results showed that VPZ-containing triple regimens were more effective than PPI-containing regimens in first- and second-line treatments, and increasing frequency of use of VPZ, AMPC, and CAM triple therapy has clearly improved the eradication rate in the first-line treatment. However, considering increasing resistance rates to antibiotics worldwide, there is no doubt that it is better to use fewer numbers of antibiotics for the treatment of *H. pylori*. Furuta and colleagues showed that effectiveness between the dual therapy of AMPC and P-CAB and the VPZ, AMPC and CAM triple therapy was nearly the same with a small sample size.^[@bibr33-1756284819858511]^ In future research, large-scale, prospective randomized trials are warranted to confirm the efficacy of the dual therapy of AMPC and P-CAB.

Age over 75 years was defined as an independent risk factor of eradication failure in both first- and second-line eradication ([Table 3](#table3-1756284819858511){ref-type="table"}). The possibility that the false-positive results in the UBT gray zone may affect the low eradication rate in elderly patients ([Table 4](#table4-1756284819858511){ref-type="table"}). Tokunaga and colleagues showed that the UBT has high sensitivity, specificity, and accuracy for diagnosis of *H. pylori* infection, with a cut-off value as 2.5%. However, the sensitivity was lower to diagnose the infection status of *H. pylori* after eradication. Then, they proposed that, to avoid false-positive results of the UBT, the gray zone of the UBT needs to be set at a level of 2.5--5.0%.^[@bibr34-1756284819858511]^ Kwon and colleagues reported that 34% of patients who received eradication treatment and thereafter judged as UBT gray zone had a false-positive result.^[@bibr17-1756284819858511]^ Moreover, they revealed a history of two or more previous *H. pylori* eradication therapies and moderate-to-severe gastric intestinal metaplasia were associated with a false-positive UBT result.^[@bibr19-1756284819858511]^ Our findings that the proportions of UBT gray zone in the second-line therapy were higher than that in first-line therapy, and that in the elderly population was higher than that in the younger population are consistent with the report of Kwon et al. because the elderly population are likely to have moderate-to-severe gastric intestinal metaplasia.^[@bibr19-1756284819858511],[@bibr35-1756284819858511]^ Urease-positive bacteria, such as *Klebsiella pneumoniae* and alpha-streptococcus, may increase the UBT level in the stomach with moderate-to-severe gastric intestinal metaplasia.^[@bibr36-1756284819858511]^ From our findings, the UBT should not be used alone in elderly patients, and the other modalities such as HpSA for *H. pylori* catalase, are recommended for evaluation of successful eradication. To improve accuracy of the UBT, adding citric acid to the UBT may be useful.^[@bibr37-1756284819858511],[@bibr38-1756284819858511]^ Noncompliance to prescribed medication in elderly patients could also affect the eradication failure.^[@bibr39-1756284819858511]^

In contrast, age of 50 years or older was not associated with successful eradication in both first- and second-line eradication therapies in our study. Nishizawa and colleagues showed the eradication rate of the first-line therapy with PPIs, but not VPZ, was significantly lower for people aged below 50 years than those aged 50 years or older.^[@bibr10-1756284819858511]^ They suggested that the cause for low eradication rate in those aged below 50 years was a high resistant rate of CAM in the young generation, especially in those aged below 30 years.^[@bibr10-1756284819858511],[@bibr40-1756284819858511]^ In our study, the proportion of patients aged below 30 years was 1.6%, and among them, those treated with PP-containing therapy were only 0.9% in the first-line therapy. Moreover, the mean age of participants in this study was higher than that in Nishizawa's report (59.4 ± 13.7 *versus* 52.3 ± 7.5). Thus, we cannot evaluate the influence of high resistant rate of CAM in the young generation in this study. Meanwhile, it was reported the elderly population had a higher resistance rate to CAM compared with the younger population.^[@bibr22-1756284819858511],[@bibr41-1756284819858511],[@bibr42-1756284819858511]^ Our results are compatible with those in previous reports.

The major limitation of the study is lack of evaluation of antibiotic resistance in *H. pylori*. Antibiotic resistance in *H. pylori* is an important factor for eradication failure. Murakami et al. reported that the eradication rate of CAM-resistant strains treated with LPZ, AMPC, and CAM triple therapy was significantly lower than that treated with VPZ, AMPC, and CAM triple therapy (40% *versus* 82%, *p* \< 0.0001);^[@bibr9-1756284819858511]^ however, there are no reports about the superiority of the VPZ, AMPC, and MTZ triple regimen for MTZ-resistant strains. In order to determine the efficacy of choices of the PPI/P-CAB for *H. pylori* eradication regimen more precisely, evaluation of antibiotic resistance in *H. pylori* is mandatory. Second, the atrophic degree of gastritis was not investigated in this study. Third, this study was retrospective, and any adverse events were not available.

In conclusion, the eradication rate showed backward increase from 2015 to 2018 in the first-line therapy because of the introduction of VPZ onto the market and increasing frequency of VPZ use. The eradication rates of first- and second-line regimens in elderly patients were lower than those in younger patients. In the elderly, many post-therapy UBT results may be false positive due to the presence of achlorhydria and overgrowth of urease-containing bacteria other than *H. pylori*.
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